PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Mitogen-activated protein kinase (MEK) inhibitors are promising cancer therapies, particularly for acute myeloid leukemia (AML).
• Acquired or inherent resistance to kinase inhibitors, often due to target kinase mutations, challenges their clinical efficacy.
• Understanding resistance mechanisms is crucial for developing effective cancer treatments.

Purpose of the Study:

• To investigate the mechanisms of resistance to MEK inhibition in acute myeloid leukemia (AML) cells.
• To identify novel causes of resistance beyond mutations in the target kinase.

Main Methods:

• Generation of a drug-resistance model by long-term treatment of AML cells with AZD6244 (selumetinib).
• Utilizing CRISPR/Cas9 gene editing technology to target exon 5 of the PTEN gene.
• Confirmation of resistance mechanisms through genetic manipulation.

Main Results:

• Acquired resistance to MEK inhibition in AML cells was primarily driven by PTEN haploinsufficiency.
• No mutations in the MEK kinase domain were identified as the cause of resistance.
• CRISPR/Cas9-mediated targeting of PTEN confirmed its role in conferring resistance.

Conclusions:

• PTEN haploinsufficiency is a novel mechanism of resistance to MEK inhibitors in AML.
• This study provides the first direct evidence of PTEN's role in MEK inhibitor resistance specifically within AML.
• Findings suggest potential therapeutic strategies targeting PTEN to overcome resistance in AML treatment.